159 related articles for article (PubMed ID: 38688429)
21. Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS).
Ansar SM; Mudalige T
Int J Pharm; 2020 Jan; 574():118906. PubMed ID: 31805309
[TBL] [Abstract][Full Text] [Related]
22. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
Jorgensen L; Hostrup S; Moeller EH; Grohganz H
Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
[TBL] [Abstract][Full Text] [Related]
23. Liposil, a promising composite material for drug storage and release.
Bégu S; Aubert Pouëssel A; Lerner DA; Tourné-Péteilh C; Devoisselle JM
J Control Release; 2007 Mar; 118(1):1-6. PubMed ID: 17250924
[TBL] [Abstract][Full Text] [Related]
24. Encapsulation, stability and in-vitro release characteristics of liposomal formulations of colchicine.
Kulkarni SB; Singh M; Betageri GV
J Pharm Pharmacol; 1997 May; 49(5):491-5. PubMed ID: 9178182
[TBL] [Abstract][Full Text] [Related]
25. Identification of pharmaceutical impurities in formulated dosage forms.
Pan C; Liu F; Motto M
J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
[TBL] [Abstract][Full Text] [Related]
26. Quantitative determination of cholesterol in liposome drug products and raw materials by high-performance liquid chromatography.
Lang JK
J Chromatogr; 1990 May; 507():157-63. PubMed ID: 2380284
[TBL] [Abstract][Full Text] [Related]
27. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
[TBL] [Abstract][Full Text] [Related]
28. Excipient variability and its impact on dosage form functionality.
Dave VS; Saoji SD; Raut NA; Haware RV
J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
[TBL] [Abstract][Full Text] [Related]
29. HPLC analysis as a tool for assessing targeted liposome composition.
Oswald M; Platscher M; Geissler S; Goepferich A
Int J Pharm; 2016 Jan; 497(1-2):293-300. PubMed ID: 26570988
[TBL] [Abstract][Full Text] [Related]
30. Excipient Stability in Oral Solid Dosage Forms: A Review.
Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
[TBL] [Abstract][Full Text] [Related]
31. Determination of the activity of maleimide-functionalized phospholipids during preparation of liposomes.
Oswald M; Geissler S; Goepferich A
Int J Pharm; 2016 Nov; 514(1):93-102. PubMed ID: 27863688
[TBL] [Abstract][Full Text] [Related]
32. Purification of pharmaceutical excipients with supercritical fluid extraction.
Ashraf-Khorassani M; Taylor LT; Waterman KC; Narayan P; Brannegan DR; Reid GL
Pharm Dev Technol; 2005; 10(4):507-16. PubMed ID: 16370180
[TBL] [Abstract][Full Text] [Related]
33. A versatile, quantitative analytical method for pharmaceutical relevant lipids in drug delivery systems.
Jeschek D; Lhota G; Wallner J; Vorauer-Uhl K
J Pharm Biomed Anal; 2016 Feb; 119():37-44. PubMed ID: 26641705
[TBL] [Abstract][Full Text] [Related]
34. Miniaturized approach for excipient selection during the development of oral solid dosage form.
Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
[TBL] [Abstract][Full Text] [Related]
35. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
[TBL] [Abstract][Full Text] [Related]
36. Managing the microbiological quality of pharmaceutical excipients.
Cundell AM
PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
[TBL] [Abstract][Full Text] [Related]
37. A new approach to accelerated drug-excipient compatibility testing.
Sims JL; Carreira JA; Carrier DJ; Crabtree SR; Easton L; Hancock SA; Simcox CE
Pharm Dev Technol; 2003; 8(2):119-26. PubMed ID: 12760562
[TBL] [Abstract][Full Text] [Related]
38. Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers.
Jebastin K; Narayanasamy D
J Liposome Res; 2023 Mar; 33(1):1-33. PubMed ID: 35543241
[TBL] [Abstract][Full Text] [Related]
39. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
Wolbert F; Brandenbusch C; Sadowski G
Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
[TBL] [Abstract][Full Text] [Related]
40. Direct compression high functionality excipient using coprocessing technique: a brief review.
Mirani AG; Patankar SP; Borole VS; Pawar AS; Kadam VJ
Curr Drug Deliv; 2011 Jul; 8(4):426-35. PubMed ID: 21235470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
